Generic Tenoretic 50 Availability

See also: Generic Tenoretic 100

Tenoretic 50 is a brand name of atenolol/chlorthalidone, approved by the FDA in the following formulation(s):

TENORETIC 50 (atenolol; chlorthalidone - tablet;oral)

  • Manufacturer: ASTRAZENECA
    Approval date: June 8, 1984
    Strength(s): 50MG;25MG [AB]

Has a generic version of Tenoretic 50 been approved?

Yes. The following products are equivalent to Tenoretic 50:

ATENOLOL AND CHLORTHALIDONE (atenolol; chlorthalidone tablet;oral)

  • Manufacturer: IPR
    Approval date: May 31, 1990
    Strength(s): 50MG;25MG [AB]
  • Manufacturer: MUTUAL PHARM
    Approval date: April 29, 1993
    Strength(s): 50MG;25MG [AB]
  • Manufacturer: MYLAN
    Approval date: October 31, 1993
    Strength(s): 50MG;25MG [AB]
  • Manufacturer: WATSON LABS
    Approval date: July 2, 1992
    Strength(s): 50MG;25MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tenoretic 50. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Tenoretic 50.

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web4)